title: What is the importance of anti-TNF agents in the treatment of luminal (inflammatory type) Crohn's disease?
authors.affiliation: Department of Gastroenterology, Ankara University, School of Medicine, Ankara, Turkey.
authors.forename: Gökhan
authors.initials: G
authors.lastname: Kabaçam
authors.forename: Murat
authors.initials: M
authors.lastname: Törüner
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003424:Crohn Disease / Q000188:drug therapy*; D006801:Humans; D000069285:Infliximab; D012074:Remission Induction / Q000379:methods; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab